logo

Avenue Therapeutics, Inc. (ATXI)



Trade ATXI now with
  Date
  Headline
8/1/2019 8:21:31 AM Avenue Therapeutics Adds Garrett Ingram To Board
3/12/2019 7:49:46 AM Avenue Therapeutics 2018 Loss Attributable To Holders $21.5 Mln Or $2.10/Shr Vs Loss Of $12.3 Mln Or $1.85/Shr Last Year
12/19/2018 8:10:15 AM Avenue Therapeutics Says First Patient Dosed In Pivotal Phase 3 Clinical Trial Of IV Tramadol
11/13/2018 6:50:46 AM Cipla Subsidiary InvaGen Announces Acquisition Agreement With Avenue Therapeutics
8/14/2018 7:33:13 AM Avenue Therapeutics Q2 Loss Attributable To Holders $4.7 Mln Or $0.45/Shr Vs Loss Of $2.4 Mln Or $0.70/Shr Last Year
5/21/2018 6:33:15 AM Avenue Therapeutics Reports Pivotal Phase 3 Trial Of IV Tramadol Achieves Primary And Key Secondary Endpoints
5/3/2018 7:35:01 AM Avenue Therapeutics Q1 Loss Attributable To Holders $10.4 Mln Or $1.03/Shr Vs Loss Of $0.7 Mln Or $0.22/Shr Last Year
3/28/2018 8:11:42 AM Avenue Gets Notices Of Allowance For Patent Applications Covering Methods Of Administration For Intravenous Tramadol
3/1/2018 7:38:18 AM Avenue Therapeutics FY Loss Attributable To Holders $12.3 Mln Or $1.85/Shr Vs Loss $3.2 Mln Or $1.11/Shr Last Year
  
 
>